April 2023
Lead Manager
DKK 1.5 billion
Accelerated Bookbuild Offering
Zealand Pharma
Lead Manager
Van Lanschot Kempen acted as Lead Manager in the DKK 1.5 billion Accelerated Bookbuild Offering by Zealand Pharma
Transaction Highlights
- Private placement by way of accelerated bookbuild offering of 6,578,948, new shares, corresponding to c. 13% of the company’s outstanding capital prior to the capital increase, at a price of DKK 228, generating gross proceeds of DKK 1.5 billion for Zealand Pharma
- The final placement price represented a discount of 5.2% vis-à-vis the last closing price ahead of transaction launch
- Zealand Pharma intends to use the proceeds to fund continued development of its proprietary pipeline of investigational peptide-based therapeutics and expects to reach several potential key milestones by extending its cash runway to mid-2026
- We are proud to have assisted this repeat client raising equity for the second time following our previous involvement in Zealand Pharma’s successful capital increase in October 2022
Company Description
Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with several pharma companies as well as commercial partnerships for its marketed products. Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with presence in the U.S, that includes Boston. For more information about Zealand’s business and activities, please visit www.zealandpharma.com.
Background Van Lanschot Kempen Life Sciences & Healthcare
In the last twelve months, Van Lanschot Kempen has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:
- Capital Markets Advisor & Placement Agent in the merger between European Biotech Acquisition Corp. and Oculis SA and the connected USD 91 million PIPE
- Lead Manager in the USD 250 million US Public Offering by CureVac
- Sole Financial Adviser to GenSight Biologics in securing a €12.0 million credit facility from Heights Capital Management
- Joint Global Coordinator and Joint Bookrunner in the SEK 416 million Capital Increase by Hansa Biopharma
- Sole Financial Adviser in SynAct Pharma’s acquisition of TXP Pharma and Joint Global Coordinator & Joint Bookrunner in SynAct Pharma’s SEK 80 million PIPE
- Joint Bookrunner in the SEK 200 million Accelerated Bookbuild Offering by Vicore Pharma
- Joint Global Bookrunner in the SEK 148 million Fully Guaranteed Rights Issue by Biovica
- Sole Financial Adviser to GenSight Biologics in securing a €35.0 million credit facility from the European Investment Bank
- Joint Global Coordinator & Joint Bookrunner in the SEK 170 million Accelerated Bookbuild offering of Xbrane Biopharma
- Co-Lead Manager in the DKK 786 million Capital Increase by Zealand Pharma
- Financial Advisor in the sale of Sanquin Reagents by Sanquin Health Solutions to Gilde Healthcare
- Financial Advisor in the up to SEK 250 million (convertible) debt financing by Mendus
- Joint Global Coordinator in the SEK 299 million Directed Share Issue by BioInvent
- Sole Global Coordinator in the SEK 200 million financing consisting of a SEK 150m PIPE and a SEK 50 million Fully Guaranteed Rights Issue by Abliva
- Joint Global Coordinator & Joint Bookrunner in the SEK 150 million Fully Guaranteed Rights Issue by SynAct Pharma